

David A Mankoff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5732169/publications.pdf>

Version: 2024-02-01

167
papers

9,305
citations

26630

56
h-index

42399

92
g-index

171
all docs

171
docs citations

171
times ranked

10020
citing authors

#	ARTICLE	IF	CITATIONS
1	Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1 Targeted ¹⁸ F-Fluorothalate PET Images of Ovarian Cancer. Journal of Nuclear Medicine, 2022, 63, 44-50.	5.0	11
2	The Development of ¹⁸ F Fluorothalate: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1. Radiology Imaging Cancer, 2022, 4, e210070.	1.6	3
3	Analysis of Routine Computed Tomographic Scans With Radiomics and Machine Learning. JAMA Oncology, 2022, , .	7.1	5
4	Principles of Tracer Kinetic Analysis in Oncology, Part I: Principles and Overview of Methodology. Journal of Nuclear Medicine, 2022, 63, 342-352.	5.0	13
5	Principles of Tracer Kinetic Analysis in Oncology, Part II: Examples and Future Directions. Journal of Nuclear Medicine, 2022, 63, 514-521.	5.0	5
6	Total Body PET – Will it Change Science and Practice?. Journal of Nuclear Medicine, 2022, , jnumed.121.263481.	5.0	5
7	¹⁸ F-Fluoroestradiol (FES) PET/CT: review of current practice and future directions. Clinical and Translational Imaging, 2022, 10, 331-341.	2.1	5
8	Novel applications of molecular imaging to guide breast cancer therapy. Cancer Imaging, 2022, 22, .	2.8	6
9	¹⁸ F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2 ⁺ Metastatic Breast Cancer. Journal of Nuclear Medicine, 2021, 62, 184-190.	5.0	20
10	Imaging endpoints of intracranial atherosclerosis using vessel wall MR imaging: a systematic review. Neuroradiology, 2021, 63, 847-856.	2.2	9
11	Radiopharmaceutical Chemistry and Drug Development – What's Changed?. Seminars in Radiation Oncology, 2021, 31, 3-11.	2.2	11
12	Analysis of Four-Dimensional Data for Total Body PET Imaging. PET Clinics, 2021, 16, 55-64.	3.0	8
13	PET Imaging in Cancer Clinical Trials. , 2021, , 1503-1516.		0
14	PET/MRI for Primary Breast Cancer: A Match Made Better by PET Quantification?. Radiology Imaging Cancer, 2021, 3, e200150.	1.6	1
15	Quantification of abdominal fat from computed tomography using deep learning and its association with electronic health records in an academic biobank. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1178-1187.	4.4	14
16	Myocardial perfusion PET imaging to evaluate coronary microvascular dysfunction in men with prostate cancer receiving androgen deprivation therapy.. Journal of Clinical Oncology, 2021, 39, 211-211.	1.6	0
17	Quantitative PET in the 2020s: a roadmap. Physics in Medicine and Biology, 2021, 66, 06RM01.	3.0	36
18	Functional 4-D clustering for characterizing intratumor heterogeneity in dynamic imaging: evaluation in FDG PET as a prognostic biomarker for breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3990-4001.	6.4	6

#	ARTICLE	IF	CITATIONS
19	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. <i>Oncologist</i> , 2021, 26, 523-532.	3.7	4
20	Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. <i>JAMA Network Open</i> , 2021, 4, e212274.	5.9	13
21	Whole-Body [18F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687. <i>Tomography</i> , 2021, 7, 139-152.	1.8	4
22	Quantitation of multiple injection dynamic PET scans: an investigation of the benefits of pooling data from separate scans when mapping kinetics. <i>Physics in Medicine and Biology</i> , 2021, 66, 135010.	3.0	4
23	A Bright Future for Nuclear Endocrinology. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1S-2S.	5.0	3
24	18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study. <i>Breast Cancer Research</i> , 2021, 23, 88.	5.0	11
25	Building the Bridge: Molecular Imaging Biomarkers for 21st Century Cancer Therapies. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1672-1676.	5.0	6
26	PET of Fibroblast-Activation Protein for Breast Cancer Diagnosis and Staging. <i>Radiology</i> , 2021, , 212098.	7.3	4
27	Clinical Translation and Adaption. , 2021, , 1-16.		0
28	Transitioning From Radiology Training to Academic Faculty: The Importance of Mentorship. <i>Current Problems in Diagnostic Radiology</i> , 2020, 49, 219-223.	1.4	12
29	Transitioning from Radiology Training to Academic Faculty: Defining Your Role and Interests. <i>Current Problems in Diagnostic Radiology</i> , 2020, 49, 227-230.	1.4	3
30	PennPET Explorer: Human Imaging on a Whole-Body Imager. <i>Journal of Nuclear Medicine</i> , 2020, 61, 144-151.	5.0	102
31	Breast Cancer ^{18F} -ISO-1 Uptake as a Marker of Proliferation Status. <i>Journal of Nuclear Medicine</i> , 2020, 61, 665-670.	5.0	24
32	Quantifying Bias and Precision of Kinetic Parameter Estimation on the PennPET Explorer, a Long Axial Field-of-View Scanner. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2020, 4, 735-749.	3.7	13
33	Update on Quantitative Imaging for Predicting and Assessing Response in Oncology. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 505-517.	4.6	2
34	Kinetic Modeling of 18F-(2S,4R)4-Fluoroglutamine in Mouse Models of Breast Cancer to Estimate Glutamine Pool Size as an Indicator of Tumor Glutamine Metabolism. <i>Journal of Nuclear Medicine</i> , 2020, 62, jnumed.120.250977.	5.0	15
35	PET Molecular Imaging as a Tool for Precision Oncology. <i>Radiology</i> , 2020, 296, 379-380.	7.3	2
36	Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort. <i>Oncologist</i> , 2020, 25, 572-578.	3.7	6

#	ARTICLE	IF	CITATIONS
37	The role of resting myocardial blood flow and myocardial blood flow reserve as a predictor of major adverse cardiovascular outcomes. PLoS ONE, 2020, 15, e0228931.	2.5	27
38	Positron Emission Tomography Imaging of Poly(Adenosine Diphosphate-Ribose) Polymerase 1 Expression in Breast Cancer. JAMA Oncology, 2020, 6, 921.	7.1	26
39	Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network. Tomography, 2020, 6, 60-64.	1.8	2
40	Assessment of the Prognostic Value of Radiomic Features in 18F-FMISO PET Imaging of Hypoxia in Postsurgery Brain Cancer Patients: Secondary Analysis of Imaging Data from a Single-Center Study and the Multicenter ACRIN 6684 Trial. Tomography, 2020, 6, 14-22.	1.8	17
41	The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. Journal of Nuclear Medicine, 2020, 61, 263S-272S.	5.0	67
42	18F-FDG-PET/CT in Breast and Gynecologic Cancer. , 2020, , 627-650.		1
43	Fulvestrant for the Treatment of Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2019, 16, 1456-1459.	3.2	21
44	Advances in PET Diagnostics for Guiding Targeted Cancer Therapy and Studying In Vivo Cancer Biology. Current Pathobiology Reports, 2019, 7, 97-108.	3.4	15
45	Automated synthesis of [11C]L-glutamine on Synthra HCN plus synthesis module. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 5.	3.9	5
46	Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [18F]FLT and [18F]ISO-1 PET/CT. Clinical Cancer Research, 2019, 25, 3063-3073.	7.0	27
47	PET oestrogen receptor imaging: ready for the clinic?. Lancet Oncology, The, 2019, 20, 467-469.	10.7	3
48	A PET Glutamate Analogue to Measure Cancer Cell Redox State and Oxidative Stress: Promise and Paradox. Cancer Research, 2019, 79, 701-703.	0.9	1
49	An Illustration of the Use of Model-Based Bootstrapping for Evaluation of Uncertainty in Kinetic Information Derived from Dynamic PET. , 2019, , .		2
50	A Simple Evaluation of the Benefit of Combined Kinetic Analysis of Multiple Injection Dynamic PET Scans. , 2019, , .		0
51	An exploration of the prognostic utility of shortened dynamic imaging protocols for PET-FDG scans. , 2019, , .		0
52	Impact of Early Radiology Research Experiences on Medical Student Perceptions of Radiology and Research. Current Problems in Diagnostic Radiology, 2019, 48, 423-426.	1.4	9
53	Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology. Neoplasia, 2019, 21, 1-16.	5.3	316
54	Test-Retest Reproducibility of ¹⁸ F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network. Journal of Nuclear Medicine, 2019, 60, 608-614.	5.0	21

#	ARTICLE	IF	CITATIONS
55	The Impact of Positron Emission Tomography with ¹⁸ F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. <i>Journal of Urology</i> , 2019, 201, 322-331.	0.4	113
56	The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1219-1235.	0.8	30
57	PET imaging for assessing tumor response to therapy. <i>Journal of Surgical Oncology</i> , 2018, 118, 362-373.	1.7	7
58	Imaging Tumor Proliferation in Breast Cancer. <i>PET Clinics</i> , 2018, 13, 445-457.	3.0	9
59	Imaging Cancer Metabolism: Underlying Biology and Emerging Strategies. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1340-1349.	5.0	50
60	Glutamate-Weighted Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Detects Glutaminase Inhibition in a Mouse Model of Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 5521-5526.	0.9	19
61	Prospective Study of Serial ¹⁸ F-FDG PET and ¹⁸ F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1823-1830.	5.0	41
62	ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. <i>PLoS ONE</i> , 2018, 13, e0198548.	2.5	21
63	Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment. <i>Journal of Biomedical Optics</i> , 2018, 24, 1.	2.6	32
64	A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 2116-2126.	8.2	100
65	Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 407-415.	7.0	88
66	Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers. <i>Cancer Letters</i> , 2017, 387, 25-31.	7.2	24
67	Quantitative PET Reporter Gene Imaging with [11C]Trimethoprim. <i>Molecular Therapy</i> , 2017, 25, 120-126.	8.2	27
68	Metabolic Imaging of Glutamine in Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 533-537.	5.0	63
69	[18F](2S,4R)-4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple-Negative Breast Cancer in Response to Glutaminase Inhibition. <i>Cancer Research</i> , 2017, 77, 1476-1484.	0.9	75
70	Making Molecular Imaging a Clinical Tool for Precision Oncology. <i>JAMA Oncology</i> , 2017, 3, 695.	7.1	63
71	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2017, 18, e653-e706.	10.7	153
72	Imaging Neoadjuvant Therapy Response in Breast Cancer. <i>Radiology</i> , 2017, 285, 358-375.	7.3	159

#	ARTICLE	IF	CITATIONS
73	Nuclear Medicine Training: What Now?. Journal of Nuclear Medicine, 2017, 58, 1536-1538.	5.0	12
74	Bacterial infection imaging with [¹⁸ F]fluoropropyl-trimethoprim. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8372-8377.	7.1	111
75	Clinical overview of the current state and future applications of positron emission tomography in bone and soft tissue sarcoma. Clinical and Translational Imaging, 2017, 5, 343-358.	2.1	2
76	Molecular Imaging and Precision Medicine in Breast Cancer. PET Clinics, 2017, 12, 39-51.	3.0	16
77	A phase I study of pazopanib in combination with escalating doses of ¹³¹ I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine. PLoS ONE, 2017, 12, e0178325.	2.5	10
78	Introduction and Overview. Journal of Nuclear Medicine, 2016, 57, 1S-2S.	5.0	3
79	Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo. , 2016, 4, 27.		23
80	The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic. Nuclear Medicine and Biology, 2016, 43, 35-41.	0.6	18
81	Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. Cancer Research, 2016, 76, 5933-5944.	0.9	105
82	ACR Appropriateness Criteria Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women. Journal of the American College of Radiology, 2016, 13, e43-e52.	1.8	13
83	ACR Appropriateness Criteria Palpable Breast Masses. Journal of the American College of Radiology, 2016, 13, e31-e42.	1.8	17
84	ACR Appropriateness Criteria® Stage I Breast Carcinoma. Journal of the American College of Radiology, 2016, 13, e53-e57.	1.8	2
85	ACR Appropriateness Criteria Breast Cancer Screening. Journal of the American College of Radiology, 2016, 13, R45-R49.	1.8	80
86	ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using ¹⁸ F-FMISO PET and MRI. Clinical Cancer Research, 2016, 22, 5079-5086.	7.0	99
87	¹⁸ F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications. Journal of Nuclear Medicine, 2016, 57, 1269-1275.	5.0	83
88	Quantitative Imaging in Cancer Clinical Trials. Clinical Cancer Research, 2016, 22, 284-290.	7.0	106
89	¹⁸ F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 983-993.	6.4	58
90	¹⁸ F-FDG PET/CT for Staging and Restaging of Breast Cancer. Journal of Nuclear Medicine, 2016, 57, 17S-26S.	5.0	135

#	ARTICLE	IF	CITATIONS
91	Management of Differentiated Thyroid Cancer in Children: Focus on the American Thyroid Association Pediatric Guidelines. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 147-164.	4.6	58
92	Novel Strategies for Breast Cancer Imaging: New Imaging Agents to Guide Treatment. <i>Journal of Nuclear Medicine</i> , 2016, 57, 69S-74S.	5.0	10
93	Development of Companion Diagnostics. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 47-56.	4.6	40
94	Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. <i>Journal of Nuclear Medicine</i> , 2016, 57, 226-230.	5.0	21
95	Serial FDG-PET to predict response, time to skeletal related events, and survival in patients with bone-dominant metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11569-11569.	1.6	1
96	Use of serial 18F-Fluorothymidine (FLT) PET and Ki-67 to predict response to aromatase inhibitors (AI) in women with ER+ breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e12039-e12039.	1.6	2
97	[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 94-101.	1.0	30
98	The Value of Establishing the Quantitative Accuracy of PET/CT Imaging. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1133-1134.	5.0	8
99	How Imaging Can Impact Clinical Trial Design. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 218-224.	2.0	19
100	How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy. <i>JAMA Oncology</i> , 2015, 1, 421.	7.1	16
101	Choosing a single target as a biomarker or therapeutic using radioactive probes. <i>Nuclear Medicine and Biology</i> , 2015, 42, 421-425.	0.6	10
102	18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1223-1228.	5.0	33
103	Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1795-1804.	3.3	37
104	A Phase II Study of 3-Deoxy- ¹⁸ F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1681-1689.	5.0	73
105	Effect of 18F-FDG Uptake Time on Lesion Detectability in PET Imaging of Early-Stage Breast Cancer. <i>Tomography</i> , 2015, 1, 53-60.	1.8	12
106	ACR Appropriateness Criteria Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women. <i>Journal of the American College of Radiology</i> , 2014, 11, 1160-1168.	1.8	29
107	A Virtual Clinical Trial of FDG-PET Imaging of Breast Cancer: Effect of Variability on Response Assessment. <i>Translational Oncology</i> , 2014, 7, 138-146.	3.7	11
108	A Phase 2 Study of ¹⁶ β-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC). <i>Molecular Imaging and Biology</i> , 2014, 16, 431-440.	2.6	80

#	ARTICLE	IF	CITATIONS
109	PET/CT imaging in cancer: Current applications and future directions. <i>Cancer</i> , 2014, 120, 3433-3445.	4.1	170
110	Activity of P-Glycoprotein, a β -Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1106-1111.	5.0	156
111	Role of PET quantitation in the monitoring of cancer response to treatment: review of approaches and human clinical trials. <i>Clinical and Translational Imaging</i> , 2014, 2, 295-303.	2.1	23
112	Molecular Imaging Biomarkers for Oncology Clinical Trials. <i>Journal of Nuclear Medicine</i> , 2014, 55, 525-528.	5.0	63
113	The contribution of physics to Nuclear Medicine: physicians' perspective on future directions. <i>EJNMMI Physics</i> , 2014, 1, 5.	2.7	6
114	Preoperative MRI Improves Prediction of Extensive Occult Axillary Lymph Node Metastases in Breast Cancer Patients with a Positive Sentinel Lymph Node Biopsy. <i>Academic Radiology</i> , 2014, 21, 92-98.	2.5	17
115	Improving lesion detectability in low uptake 18 F-FDG breast cancer by optimizing PET imaging time. , 2014, , .		0
116	Using nuclear medicine imaging in clinical practice: update on PET to guide treatment of patients with metastatic breast cancer. <i>Oncology</i> , 2014, 28, 424-30.	0.5	6
117	Evaluating the Impact of New Imaging Tests: Promises and Pitfalls. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1858-1859.	6.3	1
118	Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. <i>EJNMMI Research</i> , 2012, 2, 34.	2.5	27
119	Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. <i>Nuclear Medicine and Biology</i> , 2011, 38, 969-978.	0.6	62
120	C11-Acetate and F-18 FDG PET for Men With Prostate Cancer Bone Metastases. <i>Clinical Nuclear Medicine</i> , 2011, 36, 192-198.	1.3	76
121	Impact of Time-of-Flight PET on Whole-Body Oncologic Studies: A Human Observer Lesion Detection and Localization Study. <i>Journal of Nuclear Medicine</i> , 2011, 52, 712-719.	5.0	94
122	Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 4799-4805.	7.0	120
123	PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake. <i>Clinical Cancer Research</i> , 2011, 17, 2400-2409.	7.0	94
124	Between-Patient and Within-Patient (Site-to-Site) Variability in Estrogen Receptor Binding, Measured In Vivo by ^{18}F -Fluoroestradiol PET. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1541-1549.	5.0	65
125	ABNM Position Statement: Nuclear Medicine Professional Competency and Scope of Practice. <i>Journal of Nuclear Medicine</i> , 2011, 52, 994-997.	5.0	9
126	Imaging Studies in Anticancer Drug Development. , 2011, , 275-302.		3

#	ARTICLE	IF	CITATIONS
127	The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2â€”Response to Therapy, Other Indications, and Future Directions. <i>Journal of Nuclear Medicine</i> , 2009, 50, 738-748.	5.0	30
128	Tumor Receptor Imaging. <i>Journal of Nuclear Medicine</i> , 2008, 49, 149S-163S.	5.0	139
129	Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4449-4457.	1.6	142
130	Proliferation Imaging to Measure Early Cancer Response to Targeted Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 7159-7160.	7.0	5
131	Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and ¹⁸ F-Fluoroestradiol. <i>Journal of Nuclear Medicine</i> , 2008, 49, 367-374.	5.0	232
132	Dynamic and Static Approaches to Quantifying ¹⁸ F-FDG Uptake for Measuring Cancer Response to Therapy, Including the Effect of Granulocyte CSF. <i>Journal of Nuclear Medicine</i> , 2007, 48, 920-925.	5.0	61
133	Tumor-Specific Positron Emission Tomography Imaging in Patients: [¹⁸ F] Fluorodeoxyglucose and Beyond. <i>Clinical Cancer Research</i> , 2007, 13, 3460-3469.	7.0	154
134	Challenges in clinical studies with multiple imaging probes. <i>Nuclear Medicine and Biology</i> , 2007, 34, 879-885.	0.6	14
135	¹⁸ F-Fluoroestradiol. <i>Seminars in Nuclear Medicine</i> , 2007, 37, 470-476.	4.6	68
136	Molecular Imaging Research in the Outcomes Era. <i>Academic Radiology</i> , 2007, 14, 398-405.	2.5	39
137	Serial 2- ¹⁸ F fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). <i>Breast Cancer Research and Treatment</i> , 2007, 105, 87-94.	2.5	97
138	A definition of molecular imaging. <i>Journal of Nuclear Medicine</i> , 2007, 48, 18N, 21N.	5.0	138
139	Changes in Glucose Metabolism and Blood Flow Following Chemotherapy for Breast Cancer. <i>PET Clinics</i> , 2006, 1, 71-81.	3.0	18
140	Cancer biomarkers: a systems approach. <i>Nature Biotechnology</i> , 2006, 24, 905-908.	17.5	176
141	Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2793-2799.	1.6	357
142	Consensus recommendations for the use of ¹⁸ F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1059-66.	5.0	522
143	Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 503-514.	4.7	243
144	Residual tumor uptake of [^{99m} Tc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. <i>Cancer</i> , 2005, 103, 680-688.	4.1	43

#	ARTICLE	IF	CITATIONS
145	Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development. <i>Clinical Cancer Research</i> , 2005, 11, 2785-2808.	7.0	582
146	The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development. <i>Clinical Cancer Research</i> , 2005, 11, 7967-7985.	7.0	219
147	PET imaging of cellular proliferation. <i>Radiologic Clinics of North America</i> , 2005, 43, 153-167.	1.8	144
148	Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. <i>Journal of Nuclear Medicine</i> , 2005, 46, 274-82.	5.0	108
149	Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy ¹ . <i>Academic Radiology</i> , 2004, 11, 1115-1124.	2.5	69
150	¹⁸ F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1829-37.	5.0	92
151	Are we ready for dedicated breast imaging approaches?. <i>Journal of Nuclear Medicine</i> , 2003, 44, 594-5.	5.0	11
152	SUV varies with time after injection in (¹⁸ F)FDG PET of breast cancer: characterization and method to adjust for time differences. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1044-50.	5.0	91
153	Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1806-14.	5.0	151
154	[^{99m} Tc]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. <i>Nuclear Medicine and Biology</i> , 2002, 29, 719-727.	0.6	54
155	Use of Serial FDG PET to Measure the Response of Bone-Dominant Breast Cancer to Therapy. <i>Academic Radiology</i> , 2002, 9, 913-921.	2.5	132
156	Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. <i>Journal of Nuclear Medicine</i> , 2002, 43, 500-9.	5.0	183
157	Internal Mammary Lymph Node Drainage Patterns in Patients With Breast Cancer Documented by Breast Lymphoscintigraphy. <i>Annals of Surgical Oncology</i> , 2001, 8, 234-240.	1.5	101
158	Internal Mammary Lymph Node Drainage Patterns in Patients With Breast Cancer Documented by Breast Lymphoscintigraphy. <i>Annals of Surgical Oncology</i> , 2001, 8, 234-240.	1.5	4
159	Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [^{99m} technetium]-sestamibi scintimammography. <i>Cancer</i> , 1999, 85, 2410-2423.	4.1	107
160	Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [^{99m} technetium]-sestamibi scintimammography. , 1999, 85, 2410.		1
161	Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [^{99m} technetium]-sestamibi scintimammography. <i>Cancer</i> , 1999, 85, 2410-2423.	4.1	6
162	Application of Photoshop-based Image Analysis to Quantification of Hormone Receptor Expression in Breast Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 1997, 45, 1559-1565.	2.5	282

#	ARTICLE	IF	CITATIONS
163	Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 β -Fluorestradiol (FES). Nuclear Medicine and Biology, 1997, 24, 341-348.	0.6	80
164	Multi-Frame Data Acquisition for PET Camera Using an On-Line Microprocessor-Based System. IEEE Transactions on Nuclear Science, 1986, 33, 443-445.	2.0	2
165	Performance of Positron Imaging Systems as a Function of Energy Threshold and Shielding Depth. IEEE Transactions on Medical Imaging, 1984, 3, 18-24.	8.9	9
166	Development of Radiographic Contrast Agents for Diagnostic Imaging. , 0, , .		0
167	The role of PET in the management of brain tumors. , 0, , 8-20.		3